Literature DB >> 1700065

Structural and functional analysis of orthopoxvirus epitopes with neutralizing monoclonal antibodies.

C P Czerny1, H Mahnel.   

Abstract

Neutralizing monoclonal antibodies (MAbs) were produced in BALB/c mice immunized with live modified vaccinia virus Ankara or infected with sublethal doses of the neurovirulent vaccinia virus strain Munich 1. The immunization scheme proved to be important for obtaining MAbs of different specificity. The MAbs could be classified into three epitope groups (1 A, 1 B and 2). Immunogold electron microscopy demonstrated that the epitopes were localized on the virus surface. In immunoblotting, MAbs were reactive with polypeptides of 14K, 16K and 30K. Purified MAbs binding to the epitopes 1 A and 2 showed a 50% reduction of 100 p.f.u./0.05 ml vaccinia virus M1 with respectively 3.9 and 5.9 ng of immunoglobulin/0.05 ml. MAbs binding to the epitope 1 B neutralized the virus at a concentration of 250 ng/0.05 ml. In intraperitoneal challenge experiments, MAbs binding to the epitopes 1 A and 2 protected mice against 4 LD50 of vaccinia virus M1, but not against local lesions by subcutaneous application. MAbs against epitope 1 B had no protective effect in vivo. The three epitopes were present in 14 of 16 orthopoxviruses tested but with quantitative differences. Maximal binding (Vmax) and the antibody concentration at half-maximal binding (Km) which were calculated as for Michaelis-Menten kinetics from regression analysis of the ELISA data and the MAb concentration giving 50% plaque reduction were the basis for the evaluation. In monkey-pox virus Kopenhagen the epitopes 1 A and 1 B were absent. MAbs binding to epitope 2 reacted just as well as with vaccinia viruses. Ectromelia virus lacked all the epitopes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1700065     DOI: 10.1099/0022-1317-71-10-2341

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  22 in total

1.  Using confocal microscopy to study virus binding and entry into cells.

Authors:  A Vanderplasschen; G L Smith
Journal:  Methods Enzymol       Date:  1999       Impact factor: 1.600

2.  Vaccinia virus F12L protein is required for actin tail formation, normal plaque size, and virulence.

Authors:  W H Zhang; D Wilcock; G L Smith
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Species-level identification of orthopoxviruses with an oligonucleotide microchip.

Authors:  Sergey Lapa; Maxim Mikheev; Sergei Shchelkunov; Vladimir Mikhailovich; Alexander Sobolev; Vladimir Blinov; Igor Babkin; Alexander Guskov; Elena Sokunova; Alexander Zasedatelev; Lev Sandakhchiev; Andrei Mirzabekov
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

4.  A novel virus binding assay using confocal microscopy: demonstration that the intracellular and extracellular vaccinia virions bind to different cellular receptors.

Authors:  A Vanderplasschen; G L Smith
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

5.  Identification and characterization of vaccinia virus genes encoding proteins that are highly antigenic in animals and are immunodominant in vaccinated humans.

Authors:  W E Demkowicz; J S Maa; M Esteban
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

Review 6.  AFM review study on pox viruses and living cells.

Authors:  F M Ohnesorge; J K Hörber; W Häberle; C P Czerny; D P Smith; G Binnig
Journal:  Biophys J       Date:  1997-10       Impact factor: 4.033

7.  Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax.

Authors:  Michael S Seaman; Marissa B Wilck; Lindsey R Baden; Stephen R Walsh; Lauren E Grandpre; Colleen Devoy; Ayush Giri; Lizanne C Noble; Jane A Kleinjan; Kristen E Stevenson; Haesook T Kim; Raphael Dolin
Journal:  J Infect Dis       Date:  2010-05-01       Impact factor: 5.226

8.  Antigenic analysis of the F protein of the bovine respiratory syncytial virus: identification of two distinct antigenic sites involved in fusion inhibition.

Authors:  J P Matheise; K Walravens; A Collard; P Coppe; J J Letesson
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

9.  Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox.

Authors:  J W Hooper; E Thompson; C Wilhelmsen; M Zimmerman; M Ait Ichou; S E Steffen; C S Schmaljohn; A L Schmaljohn; P B Jahrling
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

10.  The purified 14-kilodalton envelope protein of vaccinia virus produced in Escherichia coli induces virus immunity in animals.

Authors:  C F Lai; S C Gong; M Esteban
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.